DUBLIN – Novartis AG looks to be on course to add another significant product to its portfolio of cardiovascular drugs following a positive readout from the Cantos phase III cardiovascular outcomes trial of its interleukin-beta1 (IL-beta1) inhibitor, Ilaris (canakinumab).